Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mersana Therapeutics Inc MRSN

Healthcare Biotechnology
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed... see more

Recent & Breaking News (NDAQ:MRSN)

Mersana Therapeutics Announces Publication of Two Manuscripts Detailing Preclinical Studies of the Dolaflexin Platform and Upifitamab Rilsodotin (XMT-1536) in AACR Journal Molecular Cancer Therapeutics

GlobeNewswire March 15, 2021

Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors

GlobeNewswire March 11, 2021

Mersana Therapeutics to Present Three Posters at Upcoming Virtual 2021 American Association for Cancer Research Annual Meeting

GlobeNewswire March 10, 2021

Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

GlobeNewswire February 26, 2021

Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates

GlobeNewswire February 19, 2021

Mersana Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

GlobeNewswire February 17, 2021

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 22, 2021

Carla Poulson Joins Mersana Therapeutics as Chief Human Resources Officer

GlobeNewswire January 19, 2021

Mersana Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2021

Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones

GlobeNewswire January 5, 2021

Mersana Therapeutics to Host Virtual Analyst and Investor Event

GlobeNewswire December 17, 2020

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 2, 2020

Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior Vice President and Chief Medical Officer

GlobeNewswire November 30, 2020

Mersana Therapeutics Reports Preclinical Data from Immunosynthen STING-Agonist ADC Platform and Pipeline

GlobeNewswire November 11, 2020

Mersana Therapeutics to Host Webinar Highlighting Immunosynthen STING-Agonist ADC Platform and Pipeline

GlobeNewswire November 9, 2020

Mersana Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 9, 2020

Mersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference

GlobeNewswire November 4, 2020

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates

GlobeNewswire November 2, 2020

Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

GlobeNewswire October 14, 2020

Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study

GlobeNewswire September 17, 2020